TECHNICAL SPECIFICATIONS

1.MECHANISM OF ACTION

This analog functions as a potent and selective agonist for the Growth Hormone-Releasing Hormone Receptor (GHRHR). The modifications (Acetyl-Tyr1, D-Phe2) dramatically increase its stability against plasma degradation, particularly from DPP-IV, which normally cleaves the native peptide after position 2 (Ala2). This allows it to reach and activate pituitary GHRHR more effectively. Upon binding to this Gs-protein coupled receptor, it stimulates adenylate cyclase, leading to a sustained increase in intracellular cyclic AMP (cAMP).

2.PRODUCT INDICATIONS

• Stable GHRH Agonist Studies: Investigating prolonged GH secretion dynamics in vitroand in vivodue to its enhanced pharmacokinetic profile compared to native GHRH.

• Receptor Signaling & Trafficking: Studying sustained cAMP-mediated signaling and GHRHR internalization using a degradation-resistant ligand.

• Animal Models of GH Deficiency: Administering to laboratory animals as a reliable and potent stimulator of GH for research on growth, metabolism, and aging.

• Drug Discovery & Comparative Pharmacology: Serving as a benchmark compound for evaluating the potency and stability of novel GHRH analogs or growth hormone secretagogues.

• In VitroPituitary Cell Assays: Using primary pituitary cell cultures or somatotroph cell lines to study GH synthesis and secretion with minimal peptide degradation interference.

• Structure-Activity Relationship (SAR) Research: Illustrating the impact of N-terminal modifications (acetylation, D-amino acid substitution) on peptide stability and bioactivity.

3.CLINICAL EFFICACY OF PRODUCT

• Research & Preclinical Efficacy: It is a highly effective stimulator of GH release in animal models, with potency and duration of action superior to native GHRH(1-29) due to its stability.

• Clinical Analogs: This compound belongs to a class of stabilized GHRH analogs that have been developed for clinical use. Tesamorelin (Egrifta®), an analog with similar stabilizing modifications (including a D-amino acid at position 2), is FDA-approved for treating HIV-associated lipodystrophy.

• Diagnostic Use: Analogs in this class have been used in diagnostic GH stimulation tests (e.g., GHRH + arginine test) to assess pituitary function.

• Therapeutic Potential: Research with this analog supports the therapeutic concept of using stable GHRH analogs to safely elevate GH levels for conditions like growth hormone deficiency, aging-related frailty, and metabolic disorders, though this specific molecule is not a marketed drug.




4.DELIVERY & SHIPPING


We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods 
Main Method: International Air Freight


We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.